CK 101

Drug Profile

CK 101

Alternative Names: CK-101; Covalent 3rd generation EGFR inhibitors - Fortress Biotech/NeuPharma; Irreversible third generation EGFR inhibitors - Fortress Biotech/NeuPharma; RX-518

Latest Information Update: 01 Mar 2017

Price : $50

At a glance

  • Originator Suzhou NeuPharma
  • Developer Checkpoint Therapeutics
  • Class Antibodies; Antineoplastics; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer

Most Recent Events

  • 16 Mar 2017 Checkpoint plans to initiate the phase II portion of a phase I/II trial for Non-small cell lung cancer in the second half of 2017
  • 28 Feb 2017 Checkpoint Therapeutics receives patent allowance for CK 101 in USA
  • 03 Oct 2016 Phase-I/II clinical trials in Non-small cell lung cancer (Second-line therapy or greater, Monotherapy) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top